|
Apr 29
|
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
|
|
Apr 4
|
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
|
|
Apr 4
|
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
|
|
Mar 21
|
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
|
|
Mar 21
|
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
|
|
Mar 20
|
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
|
|
Mar 8
|
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
|
|
Mar 7
|
Immunic to Participate in Investor and Scientific Conferences in March
|
|
Jan 5
|
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
|
|
Jan 5
|
Immunic, Inc. Announces Private Placement of up to $240 Million
|
|
Nov 7
|
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
|
|
Oct 4
|
Immunic to Participate in Scientific Conferences in October
|
|
Jun 27
|
These 2 ‘Strong Buy’ Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler
|
|
Jun 27
|
Pleasing Signs As A Number Of Insiders Buy Immunic Stock
|
|
Jun 26
|
Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases
|
|
Apr 27
|
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
|
|
Apr 26
|
Immunic to Participate in Investor and Scientific Conferences in May
|
|
Apr 13
|
Immunic gets a "positive surprise" from lead asset trial
|